| Page 168 | Aplastic Anemia and MDS International Foundation

Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States.

Author(s): 
Wang R, Gross CP, Halene S, Ma X
Primary Author: 
Wang R
Journal Title: 
Cancer Causes Control
Original Publication Date: 
May 2009

The potential role of socioeconomic status (SES) in the survival of

Bone Marrow Diseases: 

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Author(s): 
Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H
Primary Author: 
Steensma DP
Journal Title: 
J Clin Oncol
Original Publication Date: 
Jun 2009

PURPOSE:

Bone Marrow Diseases: 

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

Author(s): 
Nösslinger T, Tüchler H, Germing U, Sperr WR, Krieger O, Haase D, Lübbert M, Stauder R, Giagounidis A, Valent P, Pfeilstöcker M
Primary Author: 
Nösslinger T
Journal Title: 
Ann Oncol
Original Publication Date: 
Jul 2009

BACKGROUND:

Bone Marrow Diseases: 

Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.

Author(s): 
Sekeres MA, Steensma DP
Primary Author: 
Sekeres MA
Journal Title: 
Blood
Original Publication Date: 
Jul 2009

The recent approval of 3 drugs for the treatment of myelodysplastic syndromes (MDSs) has resulted in a revolution in therapeutic options that was absent a decade ago. At the same time, the changing MDS

Bone Marrow Diseases: